PMID- 21418025
OWN - NLM
STAT- MEDLINE
DCOM- 20111031
LR  - 20211020
IS  - 1875-5550 (Electronic)
IS  - 1389-2037 (Linking)
VI  - 12
IP  - 5
DP  - 2011 Aug
TI  - Bowman-Birk inhibitors from legumes and human gastrointestinal health: current 
      status and perspectives.
PG  - 358-73
AB  - Bowman-Birk inhibitors and their variants (BBI) from legumes, such as soybean, 
      pea, lentil and chickpea, are a class of naturally-occurring protease inhibitors 
      which have potential health-promoting properties within the gastrointestinal 
      tract. BBI can resist both acidic conditions and the action of proteolytic 
      enzymes, and transit through the stomach and small intestine without major 
      degradation, permitting significant amounts to reach the large intestine in 
      active form to exert their reported anti-carcinogenic and anti-inflammatory 
      properties. These potential pharmacological benefits have been linked recently to 
      the intrinsic ability of BBI to inhibit serine proteases, and the data suggest 
      that both trypsin- and chymotrypsin-like proteases involved in carcinogenesis 
      should be considered as potential targets of BBI. However, the therapeutic 
      targets and the action mechanisms of BBI remain unknown. Their elucidation will 
      provide insights into the properties of these plant protease inhibitors as 
      colorectal chemopreventive agents, providing a strong base for the development of 
      legume crops and their products as pro-nutritional, health-promoting food. The 
      deployment of modern genomic tools and genome sequence information are 
      underpinning studies of natural and induced polymorphism in BBI. Genetic markers 
      for BBI variants with improved properties can be exploited ultimately in legume 
      breeding programmes to assist the introgression of such variant genes and the 
      development of superior genotypes for human nutrition.
FAU - Clemente, Alfonso
AU  - Clemente A
AD  - Department of Physiology and Biochemistry of Nutrition, Estacion Experimental del 
      Zaidin (CSIC), Professor Albareda 1, 18008 Granada, Spain. 
      alfonso.clemente@eez.csic.es
FAU - Sonnante, Gabriella
AU  - Sonnante G
FAU - Domoney, Claire
AU  - Domoney C
LA  - eng
GR  - BBS/E/J/000CA392/BB_/Biotechnology and Biological Sciences Research 
      Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Protein Pept Sci
JT  - Current protein & peptide science
JID - 100960529
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Radiation-Protective Agents)
RN  - 0 (Trypsin Inhibitor, Bowman-Birk Soybean)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*metabolism/pharmacology/therapeutic use
MH  - Fabaceae/*metabolism
MH  - Food
MH  - Gastrointestinal Tract/drug effects/*metabolism
MH  - Humans
MH  - Neoplasms/drug therapy/prevention & control
MH  - Radiation-Protective Agents/chemistry/*metabolism/pharmacology/therapeutic use
MH  - Trypsin Inhibitor, Bowman-Birk 
      Soybean/chemistry/genetics/*metabolism/pharmacology/therapeutic use
EDAT- 2011/03/23 06:00
MHDA- 2011/11/01 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/01/14 00:00 [received]
PHST- 2011/02/14 00:00 [accepted]
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2011/11/01 06:00 [medline]
AID - CPPS-116 [pii]
AID - 10.2174/138920311796391133 [doi]
PST - ppublish
SO  - Curr Protein Pept Sci. 2011 Aug;12(5):358-73. doi: 10.2174/138920311796391133.